Anixa Biosciences(US:ANIX)2026-01-12 21:01Revenue and Income - Revenue for fiscal years 2025 and 2024 was $0, with past revenue derived from technology licensing and patent sales [172]. - Interest income decreased to approximately $673,000 in fiscal year 2025 compared to approximately $1,133,000 in fiscal year 2024 [177]. Expenses - Research and development expenses decreased by approximately $1,325,000 to approximately $5,071,000 in fiscal year 2025 from approximately $6,396,000 in fiscal year 2024 [175]. - Research and development expenses for cancer vaccines and CAR-T therapeutics in fiscal year 2025 were approximately $3,121,000 and $1,950,000, respectively [174]. - General and administrative expenses decreased by approximately $805,000 to approximately $6,630,000 in fiscal year 2025 from approximately $7,435,000 in fiscal year 2024 [176]. Cash Flow and Financial Position - Cash used in operating activities was approximately $7,173,000 during the fiscal year ended October 31, 2025 [181]. - Cash, cash equivalents, and short-term investments decreased approximately $4,750,000 to approximately $15,174,000 at October 31, 2025 [181]. - The company raised approximately $2,378,000 net of expenses through an at-the-market equity offering of 772,001 shares of common stock during the fiscal year [180]. - Expected future cash obligations related to office leases through 2029 are estimated at approximately $256,000 [182]. Net Loss and Market Risk - The net loss attributable to noncontrolling interest decreased by approximately $43,000 to approximately $101,000 in fiscal year 2025 [178]. - No quantitative and qualitative disclosures about market risk were required for the smaller reporting company [197].